Coloplast A/S Revised guidance for FY 2024/25

Core Viewpoint - Coloplast has revised its financial guidance for FY 2024/25, lowering expectations for organic growth and EBIT margin before special items [1] Financial Guidance Revision - Organic growth is now expected to be around 7%, down from the previous estimate of 8-9% [1] - EBIT margin before special items is now projected to be 27-28%, reduced from around 28% [1] Key Financial Figures for H1 2024/25 - Group organic growth was 7% in H1, with an EBIT margin before special items of 27% [6] - Organic growth rates by business area for H1: Ostomy Care 6%, Continence Care 7%, Voice and Respiratory Care 9%, Advanced Wound Care 11%, and Interventional Urology 0% [6] Q2 Performance Insights - Group organic growth was 6% in Q2, with an EBIT margin before special items of 27% [6] - Organic growth rates by business area for Q2: Ostomy Care 4%, Continence Care 8%, Voice and Respiratory Care 7%, Advanced Wound Care 10%, and Interventional Urology -1% [6] Factors Influencing Growth - Slower growth in Ostomy Care attributed to a high baseline in Europe, tender phasing in Emerging markets, and a slowdown in China [6] - Advanced Wound Care growth driven by Kerecis, which grew 30% [6] - Interventional Urology growth negatively impacted by a voluntary product recall, with an estimated impact of around DKK 35 million in Q2 [6] Updated Assumptions for Guidance - Revised organic growth guidance reflects expectations of around 0% growth in Interventional Urology for the year [6] - Reported revenue growth in DKK is now expected to be around 4%, down from previously around 7% [6] - Special items are now expected to be around DKK 400 million, increased from previously DKK 130 million, due to restructuring and asset write-downs [6]